A New Target for Chemo-Resistant Ovarian Cancer
Researchers have identified the protein TPPP3 as a driver of chemotherapy resistance in ovarian cancer. Published in the journal Cell Reports, the study reveals that blocking this protein restores the effectiveness of cisplatin, a widely used chemotherapy drug, by preventing cancer cells from stabilizing their internal structural scaffolding.
The Hidden Defense of Malignant Cells
It’s been long understood that cisplatin works by damaging cancer cells’ DNA, but this study shows that it also disrupts microtubules. Yet, tumors frequently develop resistance, causing the disease to return. New research from Michigan State University suggests these cells possess a defense mechanism involving their internal structure.
Lead researcher Sachi Horibata, an assistant professor in the Precision Health Program and pharmacology and toxicology department at the Michigan State University College of Human Medicine, explains that cancer cells reprogram their “tubulin code”—a set of structural changes that help stabilize microtubules. These microtubules serve as a cell’s internal scaffolding. By reinforcing this structure, cancer cells withstand the stress induced by chemotherapy drugs like cisplatin and carboplatin.
TPPP3 as a Biological Shield
The study pinpoints TPPP3 (tubulin polymerization promoting protein 3) as the facilitator of this resistance. Laboratory models yielded three critical observations:
- Cancer cells with higher levels of TPPP3 were better able to stabilize their internal scaffolding and withstand the effects of chemotherapy.
- Patients with lower levels of TPPP3 lived longer and responded better to treatment.
- Removing TPPP3 in experimental settings significantly restored cancer cells’ sensitivity to cisplatin, essentially stripping away their protective shield.
This discovery helps explain why some patients are told they are cancer-free, only to see the disease return. By targeting the physical structure of the cell, researchers aim to make existing therapies more effective and more durable.
Translating Research into Clinical Care
The team is now working to translate these findings into new treatment strategies. Potential strategies include developing drugs that target TPPP3 or using the protein as a biomarker to identify patients at risk of developing resistance.
These findings may also help scientists better understand some of chemotherapy’s most common side effects, including nerve damage, hair loss, and hearing loss. Because microtubules are essential in many healthy cells.
The study was a multi-institutional collaboration involving MSU, the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, the Center for Cancer Research, National Cancer Institute at the National Institutes of Health, and the Center for Biomedical Informatics & Information Technology, National Cancer Institute at the National Institutes of Health. Funding was provided by MSU, the Japan Society for the Promotion of Science, the Intramural Research Program of the National Cancer Institute, the National Institute of Neurological Disorders and Stroke, the National Heart and Lung Institute, and the Intramural Research Program of the National Institutes of Health.
Understanding the Mechanics of Resistance
What is the “tubulin code” in cancer cells?
It refers to a set of structural changes that help stabilize microtubules and support survival under stress.
Does this mean current chemotherapy drugs will change?
Not necessarily. Researchers are focusing on improving the effectiveness of existing drugs, rather than replacing them.
Why does this research matter for patient recurrence?
By understanding how tumors adapt to survive, scientists aim to block that process. This could lead to more personalized treatment plans that prevent cancer from returning after an initial “cancer-free” diagnosis.
Keep reading